Verastem Oncology (VSTM)
9.84
-0.39 (3.81%)
Upcoming Events
Latest Headlines
Verastem Oncology (VSTM) Appoints John Hayslip to Chief Medical Officer
April 18, 2024 4:05 PM - StreetInsider
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
April 18, 2024 4:05 PM - BizWire
Form DEF 14A Verastem, Inc. For: May 23
April 12, 2024 4:05 PM - SEC Filing
Form 8-K Verastem, Inc. For: Apr 09
April 9, 2024 5:11 PM - SEC Filing
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
April 9, 2024 7:00 AM - PR NewsWire
Form 4 Verastem, Inc. For: Apr 05 Filed by: Calkins Daniel
April 8, 2024 4:30 PM - SEC Filing
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 4, 2024 7:30 AM - BizWire
Form 4 Verastem, Inc. For: Mar 25 Filed by: Calkins Daniel
March 27, 2024 4:31 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 20 Filed by: Calkins Daniel
March 21, 2024 4:33 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 18 Filed by: Gagnon Robert E.
March 20, 2024 5:37 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 18 Filed by: Paterson Dan
March 20, 2024 5:34 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 18 Filed by: Stuglik Brian M
March 20, 2024 5:32 PM - SEC Filing
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
March 18, 2024 7:00 AM - BizWire
Verastem Oncology (VSTM) Misses Q4 EPS by 102c
March 14, 2024 5:43 PM - StreetInsider
Form S-8 Verastem, Inc.
March 14, 2024 5:15 PM - SEC Filing
Form 10-K Verastem, Inc. For: Dec 31
March 14, 2024 4:56 PM - SEC Filing
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
March 14, 2024 4:05 PM - BizWire
Form 4 Verastem, Inc. For: Mar 11 Filed by: Bunn Paul A.
March 13, 2024 6:19 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 11 Filed by: Stuglik Brian M
March 13, 2024 6:18 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 11 Filed by: Rowinsky Eric K
March 13, 2024 6:16 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 11 Filed by: JOHNSON JOHN
March 13, 2024 6:14 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 11 Filed by: Paterson Dan
March 13, 2024 6:13 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 11 Filed by: Calkins Daniel
March 13, 2024 6:12 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 11 Filed by: ROBERTSON MICHELLE
March 13, 2024 6:10 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 11 Filed by: Kauffman Michael
March 13, 2024 6:07 PM - SEC Filing
Form SC TO-I/A Verastem, Inc. Filed by: Verastem, Inc.
March 11, 2024 5:08 PM - SEC Filing
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to A
March 11, 2024 7:30 AM - BizWire
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
March 5, 2024 5:27 PM - BizWire
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Me
March 5, 2024 4:30 PM - BizWire
Form SC 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
February 14, 2024 7:32 PM - SEC Filing
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
February 14, 2024 10:00 AM - SEC Filing
Form SC 13G/A Verastem, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
February 14, 2024 9:20 AM - SEC Filing
Form SC 13G/A Verastem, Inc. Filed by: Vivo Opportunity, LLC
February 13, 2024 5:28 PM - SEC Filing
Mizuho Securities Assumes Verastem (VSTM) at Buy
February 9, 2024 8:28 AM - StreetInsider
Form SC TO-I Verastem, Inc. Filed by: Verastem, Inc.
February 8, 2024 4:23 PM - SEC Filing
Form 4 Verastem, Inc. For: Feb 06 Filed by: Gagnon Robert E.
February 7, 2024 4:01 PM - SEC Filing
Form 144 Verastem, Inc. Filed by: Gagnon Robert E.
February 6, 2024 4:41 PM - SEC Filing
Form SC 13G/A Verastem, Inc. Filed by: Soleus Capital Master Fund, L.P.
February 2, 2024 9:50 AM - SEC Filing
Form 8-K Verastem, Inc. For: Jan 29
January 29, 2024 4:02 PM - SEC Filing
Verastem Oncology (VSTM) Outlines Key 2024 Strategic Priorities and Upcoming Catalysts
January 29, 2024 7:04 AM - StreetInsider
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
January 29, 2024 7:00 AM - BizWire
Form 4 Verastem, Inc. For: Sep 05 Filed by: Rowinsky Eric K
January 24, 2024 4:01 PM - SEC Filing
Full Article List
